HCV genetics and genotypes dictate future antiviral strategies

Louis Papageorgiou, Chrisanthy Vlachakis, Konstantina Dragoumani, Sofia Raftopoulou, Dimitrios Brouzas, Nicolas C Nicolaides, George P Chrousos, Evangelia Charmandari, Vasileios Megalooikonomou, Dimitrios Vlachakis


At the end of the 1980s, the hepatitis C virus (HCV) was cloned and formally identified as the cause of the majority of non-A and non-B hepatitis cases. Today, around 170 million people worldwide are infected with HCV, making it five times more common than infection with the human immunodeficiency virus (HIV).  Several methods exist which mediate the spread of infection. One of the most common and efficient is sharing or re-using injecting equipment; studies have indicated that 80-90% of individuals in some populations of intravenous drug users test positive in serum HCV assays. Contracting HCV from infected blood transfusions was also a major cause of infection before screening tests were introduced in the early 1990s.  Other possible, but less common, methods of infection transmission include mother-to-child during pregnancy, sexual contact and nosocomial acquisition (for example between surgical or dialysis patients).  It appears that concurrent HIV-1 infection increases the risk of HCV transmission via the mother-to-child or sexual routes.


HCV; Hepatitis C virus; hepatitis; Genetics; antiviral


Barbato G, Cicero DO, Nardi MC, Steinkuhler C, Cortese R, De Francesco R & Bazzo R 1999 The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism. J Mol Biol 289 371-384

Bianco PR 2004 Hepatitis C NS3 helicase unwinds RNA in leaps and bounds. Lancet 364 1385-1387

Borowski P, Deinert J, Schalinski S, Bretner M, Ginalski K, Kulikowski T & Shugar D 2003 Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses. Eur J Biochem 270 1645-1653

Borowski P, Kuhl R, Laufs R, Schulze zur Wiesch J & Heiland M 1999 Identification and characterization of a histone binding site of the non-structural protein 3 of hepatitis C virus. J Clin Virol 13 61-69

Borowski P, Schalinski S & Schmitz H 2002 Nucleotide triphosphatase/helicase of hepatitis C virus as a target for antiviral therapy. Antiviral Res 55 397-412

Boulaki V, Vlachakis D, Sotiraki S & Kossida S 2013 An Up-To-Date Review of Piglet Isosporosis: New Insights and Therapeutic Perspectives. International Journal of Systems Biology and Biomedical Technologies (IJSBBT) 2 49-62

Bressanelli S, Tomei L, Roussel A, Incitti I, Vitale RL, Mathieu M, De Francesco R & Rey FA 1999 Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci U S A 96 13034-13039

Buckwold VE, Beer BE & Donis RO 2003 Bovine viral diarrhea virus as a surrogate model of hepatitis C virus for the evaluation of antiviral agents. Antiviral Res 60 1-15

Chan L, Das SK, Reddy TJ, Poisson C, Proulx M, Pereira O, Courchesne M, Roy C, Wang W, Siddiqui A, Yannopoulos CG, Nguyen-Ba N, Labrecque D, Bethell R, Hamel M, Courtemanche-Asselin P, L'Heureux L, David M, Nicolas O, Brunette S, Bilimoria D & Bedard J 2004 Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 1: Sulfonamides. Bioorg Med Chem Lett 14 793-796

Cho HS, Ha NC, Kang LW, Chung KM, Back SH, Jang SK & Oh BH 1998 Crystal structure of RNA helicase from genotype 1b hepatitis C virus. A feasible mechanism of unwinding duplex RNA. J Biol Chem 273 15045-15052

De Francesco R, Tomei L, Altamura S, Summa V & Migliaccio G 2003 Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res 58 1-16

Gordon CP & Keller PA 2005 Control of hepatitis C: a medicinal chemistry perspective. J Med Chem 48 1-20

Hesson T, Mannarino A & Cable M 2000 Probing the relationship between RNA-stimulated ATPase and helicase activities of HCV NS3 using 2'-O-methyl RNA substrates. Biochemistry 39 2619-2625

Johansson A, Poliakov A, Akerblom E, Wiklund K, Lindeberg G, Winiwarter S, Danielson UH, Samuelsson B & Hallberg A 2003 Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-Length NS3 (protease-helicase/NTPase): a comparative study of different C-terminals. Bioorg Med Chem 11 2551-2568

Kandil S, Biondaro S, Vlachakis D, Cummins AC, Coluccia A, Berry C, Leyssen P, Neyts J & Brancale A 2009 Discovery of a novel HCV helicase inhibitor by a de novo drug design approach. Bioorg Med Chem Lett 19 2935-2937

Kim DW, Gwack Y, Han JH & Choe J 1995 C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity. Biochem Biophys Res Commun 215 160-166

Kim JL, Morgenstern KA, Griffith JP, Dwyer MD, Thomson JA, Murcko MA, Lin C & Caron PR 1998 Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure 6 89-100

Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bos M, Cameron DR, Cartier M, Cordingley MG, Faucher AM, Goudreau N, Kawai SH, Kukolj G, Lagace L, LaPlante SR, Narjes H, Poupart MA, Rancourt J, Sentjens RE, St George R, Simoneau B, Steinmann G, Thibeault D, Tsantrizos YS, Weldon SM, Yong CL & Llinas-Brunet M 2003 An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426 186-189

Lauer GM & Walker BD. 2001. Hepatitis C virus infection. N Engl J Med 345 41-52

Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF & Weber PC 1999 Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 6 937-943

Lohmann V, Korner F, Koch J, Herian U, Theilmann L & Bartenschlager R 1999 Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285 110-113

Loukatou S, Fakourelis P, Papageorgiou L, Megalooikonomou V, Kossida S & Vlachakis D 2014a Ebola virus epidemic: a deliberate accident? J Mol Biochem 3 72-76

Loukatou S, Papageorgiou L, Fakourelis P, Filntisi A, Polychronidou E, Bassis I, Megalooikonomou V, Makałowski W, Vlachakis D & Kossida S 2014b Molecular dynamics simulations through GPU video games technologies. J Mol Biochem 3 64-71

Loukatou S, Papageorgiou L & Vlachakis D 2015a Optimisation of a potent series of HCV helicase drug candidates. J Mol Biochem 4 1-4

Loukatou S, Papageorgiou L & Vlachakis D 2015b Optimisation of a potent series of HCV helicase drug candidates. J Mol Biochem 4 1-4

Love RA, Parge HE, Wickersham JA, Hostomsky Z, Habuka N, Moomaw EW, Adachi T & Hostomska Z 1996 The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 87 331-342

Majid AM & Gretch DR 2002 Current and future hepatitis C virus diagnostic testing: problems and advancements. Microbes Infect 4 1227-1236

McCaffrey AP, Meuse L, Karimi M, Contag CH & Kay MA 2003 A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice. Hepatology 38 503-508

McCoy MA, Senior MM, Gesell JJ, Ramanathan L & Wyss DF 2001 Solution structure and dynamics of the single-chain hepatitis C virus NS3 protease NS4A cofactor complex. J Mol Biol 305 1099-1110

McKercher G, Beaulieu PL, Lamarre D, LaPlante S, Lefebvre S, Pellerin C, Thauvette L & Kukolj G 2004 Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template/primer substrate. Nucleic Acids Res 32 422-431

Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, Addison WR, Fischer KP, Churchill TA, Lakey JR, Tyrrell DL & Kneteman NM 2001 Hepatitis C virus replication in mice with chimeric human livers. Nat Med 7 927-933

Moradpour D, Brass V, Gosert R, Wolk B & Blum HE 2002 Hepatitis C: molecular virology and antiviral targets. Trends Mol Med 8 476-482

Nizi E, Koch U, Ontoria JM, Marchetti A, Narjes F, Malancona S, Matassa VG & Gardelli C 2004 Capped dipeptide phenethylamide inhibitors of the HCV NS3 protease. Bioorg Med Chem Lett 14 2151-2154

Papageorgiou L, Loukatou S, Koumandou VL, Makalowski W, Megalooikonomou V, Vlachakis D & Kossida S 2014 Structural models for the design of novel antiviral agents against Greek Goat Encephalitis. PeerJ 2 e664

Papageorgiou L, Loukatou S, Sofia K, Maroulis D & Vlachakis D 2016 An updated evolutionary study of Flaviviridae NS3 helicase and NS5 RNA-dependent RNA polymerase reveals novel invariable motifs as potential pharmacological targets. Mol Biosyst 12 2080-2093

Papageorgiou L, Vlachakis D, Koumandou VL, Papangelopoulos N & Kossida S 2013 Computer-aided drug design and biological evaluation of novel anti-Greek goat encephalitis agents. Int J Sys Biol Biom Tech (IJSBBT) 2 1-16

Papangelopoulos N, Vlachakis D, Filntisi A, Fakourelis P, Papageorgiou L, Megalooikonomou V & Kossida S 2013 State-of-the-art GPGPU applications in bioinformatics. International Journal of Systems Biology and Biomedical Technologies (IJSBBT) 2 24-48

Pearlman BL 2004 Hepatitis C treatment update. Am J Med 117 344-352

Phoon CW, Ng PY, Ting AE, Yeo SL & Sim MM 2001 Biological evaluation of hepatitis C virus helicase inhibitors. Bioorg Med Chem Lett 11 1647-1650

Pybus OG, Cochrane A, Holmes EC & Simmonds P 2005 The hepatitis C virus epidemic among injecting drug users. Infect Genet Evol 5 131-139

Simmonds P 2004 Genetic diversity and evolution of hepatitis C virus--15 years on. J Gen Virol 85 3173-3188

Spyropoulos B, Oikonomi E, Danelakis A, Karaboulas K, Kotsiliti E, Maridaki E, Papageorgiou L, Papalexis E, Sakellarios C & Zogogianni D 2012 A Web-Based System Supporting the Certification of the Outpatient and Emergency Departments and Providing for Post-discharge Continuity of Medical Care Software. 5th European Conference of the International Federation for Medical and Biological Engineering Springer, 721-724

Vangelatos Y, Billini M, Vlachakis D & Sophianopoulou V 2009 Molecular modelling study of PrnB, the major proline transporter of Aspergillus nidulans. FEBS Journal 171 123

Vlachakis D 2007 An Introduction to Molecular Modelling, from Theory to Application Lulu. com.

Vlachakis D, Bencurova E, Papageorgiou L, Bhide M & Kossida S 2015 Protein phosphorylation prediction: limitations, merits and pitfalls. J Mol Biochem 4 36-41

Vlachakis D, Koumandou VL & Kossida S 2013a A holistic evolutionary and structural study of flaviviridae provides insights into the function and inhibition of HCV helicase. PeerJ 1 e74

Vlachakis D, Champeris Tsaniras S, Ioannidou K, Papageorgiou L, Baumann M & Kossida S 2014 A series of Notch3 mutations in CADASIL; insights from 3D molecular modelling and evolutionary analyses. J Mol Biochem 3 97-105

Vlachakis D, Tsiliki G, Pavlopoulou A, Roubelakis MG, Champeris Tsaniras S & Kossida S 2013b Antiviral Stratagems Against HIV-1 Using RNA Interference (RNAi) Technology. Evol Bioinform Online 9 203-213

Vlachakis D, Champeris Tsaniras S & Kossida S 2012 Current viral infections and epidemics of flaviviridae; lots of grief but also some hope. J Mol Biochem 1 144-149

Vlachakis D & Champeris Tsaniras S 2016 HCV, Dengue, West Nile and now Zika; What’s next? The threat of endemic TBE relatives in Southern Europe. J Mol Biochem 5 1-3

Walker MA 1999 Hepatitis C virus: an overview of current approaches and progress. Drug Discov Today 4 518-529

Walker MP & Hong Z 2002 HCV RNA-dependent RNA polymerase as a target for antiviral development. Curr Opin Pharmacol 2 534-540

Wang W, Preville P, Morin N, Mounir S, Cai W & Siddiqui MA 2000 Hepatitis C viral IRES inhibition by phenazine and phenazine-like molecules. Bioorg Med Chem Lett 10 1151-1154

Yan Y, Li Y, Munshi S, Sardana V, Cole JL, Sardana M, Steinkuehler C, Tomei L, De Francesco R, Kuo LC & Chen Z 1998 Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci 7 837-847

Full Text: PDF


  • There are currently no refbacks.

Copyright © 2021 Journal of Molecular Biochemistry